TWI309983B - Medicine for inhibiting climacteric symptom - Google Patents
Medicine for inhibiting climacteric symptom Download PDFInfo
- Publication number
- TWI309983B TWI309983B TW93134486A TW93134486A TWI309983B TW I309983 B TWI309983 B TW I309983B TW 93134486 A TW93134486 A TW 93134486A TW 93134486 A TW93134486 A TW 93134486A TW I309983 B TWI309983 B TW I309983B
- Authority
- TW
- Taiwan
- Prior art keywords
- menopausal
- symptoms
- index
- climacteric
- inhibitor
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 239000003814 drug Substances 0.000 title description 2
- 206010027304 Menopausal symptoms Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 208000017657 Menopausal disease Diseases 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 24
- 241000238366 Cephalopoda Species 0.000 claims description 13
- 108010007568 Protamines Proteins 0.000 claims description 9
- 102000007327 Protamines Human genes 0.000 claims description 9
- 210000001550 testis Anatomy 0.000 claims description 9
- 241000251468 Actinopterygii Species 0.000 claims description 8
- 235000013402 health food Nutrition 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 229940048914 protamine Drugs 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 235000019688 fish Nutrition 0.000 claims 2
- 241000972773 Aulopiformes Species 0.000 claims 1
- 241000277331 Salmonidae Species 0.000 claims 1
- 230000004888 barrier function Effects 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 35
- 230000009245 menopause Effects 0.000 description 27
- 206010019233 Headaches Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 208000000112 Myalgia Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 208000013465 muscle pain Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000020764 Sensation disease Diseases 0.000 description 2
- 206010040026 Sensory disturbance Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 241001571540 Mesonia algae Species 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 108010016290 deoxyribonucleoprotamine Proteins 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000003108 foot joint Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000002515 guano Substances 0.000 description 1
- 210000002478 hand joint Anatomy 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000020861 perceptual disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000012810 sudden onset of fever Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- -1 troches Substances 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000004865 vascular response Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
1309983 (1) 九、發明說明 【發明所屬之技術領域】 本發明係關於由攝取而可有效地抑制更年期中之各種 - 不舒適症狀,亦即更年期障礙之更年期障礙抑制劑以及含 __ 該有效量之健康食品者。. t 【先前技術】 由壯年期至老年期間,隨著年齡的增加而伴隨著身體 Φ 的老化,不僅人的外觀變化(肌力降低、肥滿、脫毛、斑 點或皴紋增加等)或精神力降低,多伴隨有內分泌系統之 功能降低或異常。激素例如女性激素(雌性激素或黃體激 素)的減少,帶來女性所謂的更年期障礙。不僅女性,最 近,起因自男性激素(睪九激素)減少之男性更年期障礙 亦成爲問題。 更年期障礙,尤其對於女性有深刻的問題,誘發如下 所示之各種症狀。 · (a )月經異常 月經週期的縮短或延長、月經次數減少及不正常出血 等。 (b )血管反應系統的變化 熱潮紅或血氣上衝等之突然發生的發熱感。 -5- (2) 1309983 (c )精神症狀 失眠或憂鬱症狀等。 (d )泌尿生殖器症狀 頻尿或尿失禁等。 (e)其他 骨質疏鬆症、高脂血症及動脈硬化等。 ,可舉例如 易缺乏之女 液或貼附劑 法。其他, 如亦嘗試由 )以抑制更 及特開2003 之食品,可 作爲女性之更年期障礙之代表性治療方法 激素補充療法。激素補充療法係更年期女性容 性激素(雌性激素或黃體激素),由使用內服 型態之製劑補充,治療或抑制更年期障礙之方 亦可使用例如漢方療法。 除了如激素補充療法或漢方療法以外,例 每曰攝取含特定成份之食品(所謂的健康食品 年期障礙(參考例如特開2〇〇 1 - 069946號公報 - 1 1 3 1 1 7號公報)。有效地抑制更年期障礙用 舉例如含異黃酮或骨質蛋白質之食品。 專利文獻1 :特開200 1 - 069946號公報 專利文獻2 :特開2〇〇3 - 1 I3 1 I7號公報 【發明內容】 發明之揭示 發明所欲解決之課題 -6- (3) 1309983 上述之激素補充療法係有治療或抑制更年期障礙之效 果,相反地,亦有產生各種副作用的危險(例如增大乳癌 或子宮癌等之發病率等)。另外,激素補充療法或漢方療 法係必須基於專業醫師的指示,嚴格地進行,稱不上爲簡 便的方法。 傳統上,即使對於抑制更年期障礙具有效果之食品( 或添加於食品之特定成份),對於更年期障礙之全體多種 症狀(症候群),當然並未顯示效果受到具體地實際證實 之有效性。 因此,強烈希望任何人都可簡便地且安全地實施更年 期障礙之抑制手段。 本發明係爲解決上述傳統技術之問題點者,作爲該目 的係提供可經口地且容易地攝取,由規則地(例如每曰) 攝取’可有效地抑制更年期障礙之更年期障礙抑制劑及含 該有效量之健康食品。 課題之解決手段 本發明者等努力硏究關於抑制更年期障礙之結果,發 現核精蛋白(nucleoprotamine )係可有效地抑制更年期障 礙而完成本發明。 本發明之更年期障礙抑制劑係以含核精蛋白爲有效成 份爲特徵。 上述核精蛋白係可使用得自魚類精巢之核精蛋白。 上述魚類可爲鮭魚、鱒魚、緋魚或鳕魚。 (4) (4)1309983 本發明之健康食品係以含有效量之本更年期障礙抑制 劑爲特徵。 發明之功效 本發明之更年期障礙抑制劑係可容易地經口攝取,亦 無副作用,由適量地攝取,可有效地抑制大範圍的更年期 障礙。 另外’本發明之健康食品係含有效量之本更年期障礙 抑制劑’可爲固體、液體、透明凍膠狀及糊狀等之各種型 態’因爲可適當地選擇最適合之型態,所以適合每日攝取 用以實施發明之最佳型態 本發明之更年期障礙抑制劑之有效成份之核精蛋白係 存在於脊椎動物之成熟精核中之鹼性蛋白質之魚精蛋白與 核酸鍵結所成之複合體者,形成精子之染色質。 魚精蛋白係分子量小(通常分子量爲1萬以下),構 成胺基酸之大部份係鹼性胺基酸,尤其爲精胺酸,來自精 胺酸之氮係相當於總含氮量之2 5至9 0 %,通常不含酸性胺 基酸。 精胺酸係具有多種生理作用,有鎭靜效果、刺激內分 泌效果及保護消化道功能之效果等。 核精蛋白係多含於魚類,例如鮭魚、鱒魚、鲱魚或鳕 魚之精巢中,例如可以將魚類之精巢除去皮、筋及血管等 -8- (5) 1309983 之後,以乾燥或萃取等之常用方法精製而製 狀、顆粒狀、糊狀及液狀等之各種型態。 由攝取核精蛋白,可同時攝取魚精蛋白 核酸中有去氧核糖核酸(DNA )與核糖 ,保存生物之遺傳訊息。魚類精巢中係含有 呤(A )、胸腺嘧啶(T )、鳥糞嘌呤(G ). )之四種核酸爲組成要素所成之DNA。核酸 細胞,防止老化之效果。 本發明之更年期障礙抑制劑之使用型態 限制,例如粉末、顆粒、錠劑、膠囊劑、透 之各種型態之健康食品(含健康飮料)等。 爲例如水溶液、懸濁液等。可直接使用核精 明之更年期障礙抑制劑,因應所需,亦可適 的有效成份(例如維生素類等)。 本發明之更年期障礙抑制劑中之核精蛋 本發明之健康食品中之本更年期障礙抑制劑 應需要而可適當地選擇。 本發明之健康食品係本更年期障礙抑制 含添加於通常食品所得者。 本發明之更年期障礙抑制劑係適合每曰 日攝取如0.1至10g,以0.2至5g之量爲宜。本 期障礙抑制劑係可每日分1至3次攝取,但依 更年期障礙之症狀等而適當地增減攝取量。 造,可爲粉末 及核酸。 核酸(RNA) 大量的以腺嘌 及胞嘧啶(C 係具有活化 ,並無特別的 明凍膠、漿糊 健康飮料係可 蛋白作爲本發 量地添加其他 白之含有率或 之含有率係因 劑以外,亦包 ,例如相當每 :發明之更年 年齡、體重及 (6) (6)1309983 【實施方式】 實施例 由下述之實施例更詳細地說明本發明。 (1 )製造本發明之更年期障礙抑制劑 以下述步驟’由鮭魚精巢製造本發明之更年期障礙抑 制劑。 i :鮭魚精巢之前處理 取1 0 0 0 g之鮭魚精巢,進行去血及水洗。瀝水後,加 入3 0 0ml的水,磨碎、攪拌而得懸濁液。 I i :粉末化處理 過濾上述懸濁液,除去精巢的皮等之固形物後,以噴 霧乾燥器噴霧乾燥而得粉末狀物質。1309983 (1) IX. INSTRUCTIONS OF THE INVENTION [Technical Field] The present invention relates to an inhibitor of menopausal disorder which is effective in suppressing various types of discomfort during menopause, that is, menopausal disorders, and __ A quantity of healthy food. t [Previous technique] From the aging to the old age, with the increase of age, accompanied by the aging of the body Φ, not only the change in appearance of the human body (reduced muscle strength, plump, hair removal, increase of spots or crepe lines, etc.) or spirit The force is reduced, and the function of the endocrine system is often reduced or abnormal. The reduction of hormones such as female hormones (estrogen or lutein) leads to so-called menopausal disorders in women. Not only women, but also male menopausal disorders, which are caused by a decrease in male hormones (睪九激素), have become a problem. Menopausal disorders, especially for women, have profound problems that trigger the symptoms shown below. · (a) Abnormal menstruation The shortening or prolongation of the menstrual cycle, the reduction in the number of menstrual cycles, and abnormal bleeding. (b) Changes in the vascular response system The sudden onset of fever such as hot flashes or blood gas rushing. -5- (2) 1309983 (c) Psychiatric symptoms Insomnia or depression symptoms. (d) genitourinary symptoms, frequent urination or urinary incontinence. (e) Other osteoporosis, hyperlipidemia, and arteriosclerosis. For example, it is easy to lack a female liquid or a patching method. Others, such as try to inhibit the food of the special 2003, can be used as a representative treatment for menopausal disorders in women. Hormone supplement therapy. Hormone-supplementation therapy is a menopausal female hormone (estrogen or luteinizing hormone) that is supplemented with a formulation that uses internal medicine to treat or inhibit menopausal disorders. For example, Hanfang therapy can also be used. In addition to, for example, hormone supplementation therapy or Hanfang therapy, foods containing specific ingredients are taken every time (the so-called health food age disorder) (refer to Japanese Laid-Open Patent Publication No. Hei. No. Hei. No. Hei. No. 2-069946 - 1 1 3 1 1 7 ) For the purpose of effectively suppressing menopausal disorders, for example, foods containing isoflavones or bone protein are disclosed. Patent Document 1: JP-A No. 2001-069946 Patent Document 2: JP-A-2-31-I1 1 I7 】 Disclosure of the Invention Problems to be Solved by the Invention-6- (3) 1309983 The above-mentioned hormone supplementation therapy has the effect of treating or inhibiting menopausal disorders, and conversely, it also has the risk of causing various side effects (for example, increasing breast cancer or uterine cancer) In addition, hormonal supplementation therapy or Hanfang therapy must be carried out strictly according to the instructions of a professional physician, and it is not a simple method. Traditionally, even foods that are effective in inhibiting menopausal disorders (or addition) For the specific ingredients of food, for the various symptoms (symptoms) of menopausal disorders, of course, the effect has not been shown to be specifically verified. Therefore, it is strongly desired that any person can easily and safely implement the means for suppressing menopausal disorders. The present invention is to solve the problems of the above conventional techniques, and as such a purpose, it is possible to provide oral and easy ingestion. In order to prevent the menopausal disorder, the inventors of the present invention have tried to infect the menopausal disorder which is effective in suppressing menopausal disorders, and the health food containing the effective amount. The nucleoprotamine system can effectively inhibit menopausal disorders and complete the present invention. The climacteric inhibitor of the present invention is characterized by containing nuclear fibrin as an active ingredient. The above nuclear protamine can be obtained from a fish testis core. The above-mentioned fish may be squid, squid, squid or squid. (4) (4) 1309983 The health food of the present invention is characterized by containing an effective amount of this climacteric disorder inhibitor. The climacteric disorder inhibitor can be easily orally ingested, has no side effects, and is ingested in an appropriate amount, which is effective A wide range of menopausal disorders. In addition, the health food of the present invention contains an effective amount of the present menopausal disorder inhibitor, which can be various types of solid, liquid, transparent jelly, and paste, etc. It is suitable for daily intake of the best form of the invention. The nuclear protamine of the active ingredient of the menopausal inhibitor of the present invention is a basic protein of fish that is present in the mature sperm nuclei of vertebrates. The complex of protein and nucleic acid bonds forms the chromatin of sperm. The protamine protein has a small molecular weight (usually a molecular weight of 10,000 or less), and most of the amino acids are basic amino acids, especially Arginine, a nitrogen system derived from arginine, corresponds to 25 to 90% of the total nitrogen content and is usually free of acidic amino acids. The arginine has a variety of physiological effects, such as a calming effect, an stimulating endocrine effect, and an effect of protecting the function of the digestive tract. The nuclear protamine is mostly contained in fish, such as the testis of squid, squid, squid or squid. For example, the testis of fish can be removed from the skin, tendons and blood vessels, etc. -8- (5) 1309983, followed by drying or extraction. The conventional methods are refined in various forms such as a form, a granule, a paste, and a liquid. By ingesting nuclear protamine, it is possible to simultaneously take protamine. The nucleic acid contains deoxyribonucleic acid (DNA) and ribose, and preserves the genetic information of the organism. The fish testis contains four kinds of nucleic acids: 呤 (A), thymine (T), and guano (G). Nucleic acid cells prevent the effects of aging. The use form of the menopausal disorder inhibitor of the present invention is limited, for example, powders, granules, troches, capsules, various types of health foods (including healthy foods), and the like. For example, an aqueous solution, a suspension, or the like. Nuclear savvy menopausal inhibitors can be used directly, and appropriate active ingredients (such as vitamins) can be used as needed. The nucleolipid in the climacteric inhibitor of the present invention The present climacteric inhibitor in the health food of the present invention may be appropriately selected as needed. The health food of the present invention is intended to inhibit the menopause of the present invention. The menopausal disorder inhibitor of the present invention is suitable for ingestion of, for example, 0.1 to 10 g per day, preferably in an amount of 0.2 to 5 g. In this case, the inhibitor of the disorder can be ingested one to three times a day, but the intake is appropriately increased or decreased depending on the symptoms of the menopausal disorder. It can be made into powders and nucleic acids. Nucleic acid (RNA) A large number of adenine and cytosine (C system is activated, there is no special gelatin, paste, healthy protein, protein as the amount of other white content or the content rate of the source In addition to the agent, it is also included, for example, equivalent: the age of the invention, the body weight, and (6) (6) 1309983. [Embodiment] The present invention will be described in more detail by the following examples. (1) Manufacture of the present invention The menopausal disorder inhibitor is manufactured by the following steps: 'The climacteric inhibitor of the present invention is made from the squid testis. i: The squid testis is taken before the squid testis to remove blood and water. After draining, add 300 ml. The water is ground and stirred to obtain a suspension. I i : The suspension is filtered by a powdering treatment to remove the solid matter such as the skin of the testis, and then spray-dried in a spray dryer to obtain a powdery substance.
Iii :洗淨及回收 以乙醇洗淨上述之粉末狀物質,除去乙醇可溶解物及 水份,減壓乾燥成粉末狀物,而得1 8 0 g之本更年期障礙 抑制劑。 如此所得之本更年期障礙抑制劑係含有核精蛋白爲主 要成份之淡黃色粉末,其化學性質及物理性質係如下所述 〇 核酸含有率:25至50質量% 蛋白質含有率:25至60質量% 灰份含有率:5至15質量% 寧海準反應(Ninhydrin reaction):陽性 -10- (7)1309983 (2 )本發明之更年期障礙抑制劑之評估手段 爲客觀地評估更年期障礙之程度,使用更年期指數( Kupperman index )。更年期指數係基於下述表1而計算。Iii: Washing and recovery The above-mentioned powdery substance was washed with ethanol to remove the ethanol soluble matter and water, and dried under reduced pressure to a powder to obtain 180 g of this menopausal inhibitor. The present menopausal disorder inhibitor thus obtained is a pale yellow powder containing nuclear protamine as a main component, and its chemical and physical properties are as follows: 〇 nucleic acid content: 25 to 50% by mass Protein content: 25 to 60% by mass Ash content: 5 to 15% by mass Ninhydrin reaction: positive-10-(7)1309983 (2) The evaluation method of the climacteric inhibitor of the present invention is to objectively evaluate the degree of menopausal disorder, using menopause Kupperman index. The menopause index is calculated based on Table 1 below.
-11 - (8) 1309983 表1:更年期指數之計算表 症狀群 症狀 評估因素 種類 強度 血管運動神經 障礙般症狀 臉發熱 容易出汗 腰或手腳冰冷 感覺喘不過氣 3 · 2 · 1 · 0 4 知覺障礙般症 狀 手腳發麻 手腳感覺遲鈍 3 · 2 · 1 · 0 2 失眠 夜晚無法成眠即使 夜晚能成眠,仍容 易醒來 3 · 2 · 1 · 0 2 神經質 容易興奮 神經質 3 · 2 · 1 · 0 2 憂鬱 爲小事煩惱 容易憂鬱 3 · 2 · 1 · 0 1 暈眩 頭暈或想吐 3 · 2 · 1 · 0 1 全身倦怠 容易疲倦 3 · 2 · 1 · 0 1 關節痛·肌肉 痛 肩膀酸痛·腰痛· 手腳關節疼痛 3 · 2 · 1 · 0 1 頭痛 頭痛 3 · 2 · 1 · 0 1 心悸亢進 心臟動悸 3 · 2 · 1 · 0 1 犠行感 感覺螞蟻爬行在皮 膚上 3 · 2 · 1 · 0 1 -12- (9) 1309983 〈更年期指數之計算〉 以下係說明更年期指數之計算方法。如表1所示之症 候群之1 1種各症候,將症候(症狀)強度以0至3之數字表 示。各數字之意味係如下所示。 3 :強 2 :中等程度 1 :弱 〇 :無 表1之症候群所屬之各症候係可再細分爲幾種症狀。 以知覺障礙般症狀爲例,知覺障礙般症狀係分爲症狀「手 腳發麻」與症狀「手腳感覺遲鈍」之2種。其次,關於各 個症狀「手腳發麻」與症狀「手腳感覺遲鈍」,將症狀強 度以0至3之數字表示。表1之症候群所屬之各症候之更年 期指數係由下述之式(I )計算。 式(I ):各種症狀強度之最高點X評估因素 具體上,例如症狀「手腳發麻」之強度爲1,症狀「 手腳感覺遲鈍」之強度爲0時,「知覺障礙般症狀」之更 年期指數係1 (最高點)X2 (評估因素)=2。 〈基於更年期指數(合計),判定更年期障礙的程度 > 表1所示之1 1種之各症候之更年期指數之合計〔更年 期指數(合計)〕係成爲對更年期障礙之更年期指數。更 年期障礙的程度係由更年期指數(合計),基於下述之基 準而判定。 -13- (10) 1309983 3 5以上:重症 21至34 :中等症 1 6至2 0 :輕症 〈更年期障礙治療效果之指標:停經指數之計算〉 作爲更年期障礙治療效果之指標係使用停經指數。停 經指數係由下述式(Π )而計算。 式(Π ):治療後之更年期指數(合計)/治療前之 更年期指數(合計) 更年期障礙之治療效果係由停經指數,基於下述之基 準而判定。 0.3以下:顯著 〇 . 3至0.7 :有效 0.7以上:無效 (3 )本發明之更年期障礙抑制劑之評估結果 52歲至68歲之女性合計25人,攝取ig/日之本發明之 更年期障礙抑制劑’於6 0天後,算出全體人員之更年期指 數。結果如下述之表2至表4所示。 (11)1309983 眯 m-11 - (8) 1309983 Table 1: Calculation of Menopause Index Symptoms Symptoms Evaluation Factors Types Intensity Vasomotor Neurological Disorders Symptoms Facial fever Fever sweating or cold hands and feet Feeling breathless 3 · 2 · 1 · 0 4 Perception Obstacle-like symptoms, hands and feet, numb hands and feet, feeling sluggish 3 · 2 · 1 · 0 2 Insomnia can't sleep at night, even if you can sleep at night, it is easy to wake up 3 · 2 · 1 · 0 2 Neurotic is easy to excite neurotic 3 · 2 · 1 · 0 2 Melancholy troubles for small things, easy depression 3 · 2 · 1 · 0 1 dizziness, dizziness or vomiting 3 · 2 · 1 · 0 1 body burnout, easy fatigue 3 · 2 · 1 · 0 1 joint pain, muscle pain, shoulder pain, low back pain Hand and foot joint pain 3 · 2 · 1 · 0 1 Headache headache 3 · 2 · 1 · 0 1 palpitations into the heart 3 · 2 · 1 · 0 1 Sense of feeling ants crawling on the skin 3 · 2 · 1 · 0 1 -12- (9) 1309983 <Calculation of the Menopause Index> The following is a description of the calculation method for the menopause index. As for each of the symptoms of the syndrome shown in Table 1, the intensity of symptoms (symptoms) is represented by a number from 0 to 3. The meaning of each number is as follows. 3: Strong 2: Moderate 1: Weak 〇: None The symptoms of the syndromes in Table 1 can be subdivided into several symptoms. In the case of symptoms such as sensory disturbances, symptoms such as sensory disturbances are classified into two types: symptoms, numbness of the hands and feet, and symptoms of "slow hands and feet." Next, regarding the symptoms, "the numbness of the hands and feet" and the symptoms "the feelings of the hands and feet are slow", the symptom intensity is represented by a number from 0 to 3. The menopausal index of each symptom to which the syndrome of Table 1 belongs is calculated by the following formula (I). Formula (I): The highest point of each symptom intensity X evaluation factor Specifically, for example, the intensity of the symptoms "hands and feet numbness" is 1, the symptom "the feeling of hands and feet is slow" is 0, the menopausal index of "perceptual symptoms" Line 1 (highest point) X2 (evaluation factor) = 2. <Based on the menopause index (total), the degree of menopausal disorder is judged > The total of the menopausal index of each of the 11 types of symptoms shown in Table 1 (the menopause index (total)) is a menopausal index for menopausal disorders. The degree of menopausal disorder is determined by the menopause index (total) based on the following criteria. -13- (10) 1309983 3 5 or more: Severe 21 to 34: Moderate 1 6 to 20: Mildness: Index of treatment effect of menopausal disorder: calculation of menopausal index As an indicator of treatment effect of menopausal disorder, use of menopause index . The menstrual index is calculated by the following formula (Π). Formula (Π): Post-treatment menopausal index (total)/pre-treatment Menopause index (total) The therapeutic effect of menopausal disorder is determined by the menopause index based on the following criteria. 0.3 or less: significant 〇. 3 to 0.7: effective 0.7 or more: invalid (3) evaluation result of the climacteric disorder inhibitor of the present invention, a total of 25 women aged 52 to 68, ig/day of the invention inhibits menopause After 60 days, the agent's menopause index was calculated. The results are shown in Tables 2 to 4 below. (11)1309983 眯 m
N 蘅 φN 蘅 φ
S 蘧 » 壯S 蘧 » Zhuang
U Η 餾 55歲女性 游 〇 〇 ——寸 —Ο (N Ο Ο 〇 ^― ·— fVj —— —*- ο ο m m ο ο ο ο 一一 - ΓΝί O CN CC Ο Ο 〇 Ο Ο 〇 一 —CS 一——( -Η — ο ο m m 一 — ο ο Ο 〇 87歲女性| 逛 Ο Ο Ο Ο 〇 Ο Ο 〇 ——04 〇 一 fNJ ο ο ο ο ο ο ο —一 ο ο ο ο —— ^sD e Ο Ο Ο Ο 〇 Ο Ο 〇 *—1 >—1 (N O ο ο ο ο ο ο ο —— ο ο ο ο Ο 〇 id 55歲女性 迤 ——Ο Ο <Ν —Ο (N ——fN —Ο (N ——— —一 ο ο Ο Ο ο ο ο ο Ο 〇 ο e <Ν Ο Ο 〇〇 ——(S (N (S 寸 (S o吋 一—— —一 — ο ο ο ο 一— Ο 〇 (Ν (Ν 59歲女性 班 Ο Ο Ο Ο Ο Ο Ο 〇 Ο Ο 〇 o o o ο ο ο ο ο ο ο ο ο ο ο ο ο 〇 C5 ο S ο ο ο ο ο Ο Ο 〇 (Ν (N 寸 ——<N -ο - ο ο (Ν (Ν —Η 一 ◦ ο Ο 〇 二 58歲女性 班 ο 一 ο ο 寸 0 — 01 Ο CM 呀 o o o ο ο ο ο ο ο ο —— ο ο —一 Ο 〇 (Ν S —< <Ν Ο fN ΟΟ —Ο (N Ο (N对 o o o ο ο ο 一一 CM (Ν (Ν <Ν ο ο ——' Ο 〇 55歲女性 班 Ο Ο Ο Ο Ο Ο Ο 〇 Ο Ο 〇 o o o ίΝ (Ν CN ο ο —— —— ο ο ο ο Ο 〇 对 S (Ν Ο Ο Ο 00 Ο Ο 〇 Ο Ο 〇 —(N 对 (Ν (Ν ο ο — —— ο ο 一一 Ο 〇 卜 61歲女性 班 Ο Ο Ο 一对 Ο Ο 〇 Ο Ο 〇 o o o Ο Ο Ο ο ο —一 ο ο Ο 〇 r- S ο ο ο —寸 Ο Ο 〇 Ο Ο 〇 o o o ο ο ο —— ΓΜ (Ν (Ν Γνΐ —— ο ο —— 二 59歲女性 班 ο ο ο ο ο Ο Ο 〇 Ο Ο 〇 o o o ο ο ο ο ο —— —— ο ο ο ο Ο 〇 (Ν e ..ο ο 寸 Ο Ο 〇 Ο Ο 〇 o o o ο ο ο ο ο —— —— ο ο ο ο Ο 〇 oc 56歲女性 班 ο ο ο ο ο Ο Ο 〇 Ο Ο 〇 o o o ο ο ο ο ο Ο Ο 一— ο ο ο ο Ο 〇 — —一 〇 〇 呀 Ο Ο 〇 Ο Ο 〇 o o o "° Μ ο ο ο ο m m ο ο ο ο Ο 〇 00 驟 <1mtl P 體 鹬 s ft: S IS ss 癒 3 S S 鹬崦链If壯 磐娣鹽審K 簏 mu 鹬鞮s _ _壯 \fh K 騮 峨 娣 e n±^ rn m3 链 S 坩眾§5 堡®肚 搭S K » | 魏® _麵壯 wmn i® ^ W- W » 七峨壯 載姊)Κ m録 is _壯 容易疲倦 :更年期指數 賴 按 S w1» a • ie mm ,咖 蠢1 11W, :頭痛 :更年期指數 心臟動悸 更年期指數 ~Μ 键 抝 颦3S S踩 _肚 mn 更年期指數合計 症候群 血管運動 神經障礙 知覺障礙 般病狀 失眠 神經質 憂鬱 頭暈 全身倦怠 關節痛· 肌肉痛 頭痛 心悸亢進 蟻行感 -15- (12)1309983 58歲女性 >—1 — 〇 〇 ^ Ο Ο 〇 ο ο ο —Ο (N ο ο ο ο ο ψ^, 一一 ο ο Ο 〇 Ο 〇 00 wm Ψ-^I psj >—1 ·—1 (Ν —Ο (N ο ο ο ο ο Ψ-^ τ-π (N CN ο ο Ο 〇 Ο 〇 ro 55歲女性 麥 —Ο Ο 〇 呀 —Ο (Ν —Ο (Ν O -- <N ο ο ο ο ο ο ο Ο 〇 一― Ο 〇 Ο 〇 一 Ο Ο Ο Ο 〇 —Ο (Ν Ο Ο Ο O — fN ο ο ο ο ο ο ο —'— r4 CM Ο 〇 Ο 〇 卜 68歲女性 鹚 〇 — m Ο Ο Ο Ο — (Ν O r^t \D —-ο — ο ο m m m —— Ο 〇 —— Os S —〇 m — ^ CM Ο — (Ν 一(N寸 ο ο ο —— (Ν tN m m —'― —一 Ο 〇 «Ν m 64歲女性 逛 fN (N — m 2 —— —(Ν寸 *— (N 寸 CN — CNJ ο ο 一 ” fN| CN ο ο CN (Ν Ο 〇 ON <N e m (N — m fN ^ — —(N tJ- m (Ν m ο ο (N CN (Ν (N ο ο <Ν (Ν Ο 〇 in m 57歲女性 班 — O O O 寸 Ο Ο Ο Ο Ο Ο —Ο (N ο ο ο ο ο CM (N CM OJ ο ο Ο 〇 Ο 〇 o 一 o o o 寸 ο ο ο ο ο ο o o o ο ο ο ο ο tN (N CM (N ο ο Ο 〇 Ο 〇 00 52歲女性 輕 Ο Ο (Ν Ο 00 (Ν —寸 ο ο ο o o o ο ο ο ο ο — CS CS ο ο Ο 〇 Ο 〇 Ο Ο ΓΝ| Ο 00 (Ν Ο呀 —Ο CNJ o o o ο ο ο ο ο H 一 <N rJ ο ο Ο 〇 Ο 〇 Γ- 53歲女性 班 ο ο ο ο ο Ο Ο Ο Ο — (Ν O — <N ο ο ο ο ο o o —一 ο ο Ο 〇 Ο 〇 «〇 e ·— ζ^ι —0(Ν Ο CN廿 〇 —< (Nj ο —— ο ο 一一 —— —:— 一— Ο 〇 卜 53歲女性 ο ο ο ο ο Ο Ο Ο ο ο ο o o o ο ο ο ο ο o o r4 〇J ο ο Ο 〇 Ο 〇 CN 症 ο ο ο ο ο ο ο ο ο ο ο o o o ο ο ο ο ο o o (Ν (N ο ο Ο 〇 Ο 〇 o 56歲女性 ο ο ο ο ο ο ο ο ——(Ν o o o ο ο ο ο ο T—— (Ν (N ο ο Ο 〇 Ο 〇 •/"l g ο ο ο ο ο ο ο ο ——(Ν o o o ο ο ο ο ο w — CM fN 一 一 Ο 〇 Ο 〇 更年期指數合計 6 騷 Μ * 餾鏟 !t S US SS « B阼豳踩 鎞崦锊胩 磐妫B馨W 葚 mmm 鹬飽s S S UU VLU wj ΠΤ1 up 圜 掷 s OH S *ga> 撼s w 線 w | 截_(餘 峨鍵肚 ίφ ft 1»< 麵1 藏 i® g 條_ 05 七嘛壯 翁娣w +]錄 i班 is s w 容易疲倦 更年期指數 艇 谈 ε ΙΕ^ ΠΕΕ s i!f ,um «s i扮 m 1¾ 頭痛 1 更年期指數 1 心臟動悸 更年期指數 Ή 键 相 S錄 |35 mu 症候群 血管運動 神經障礙 知覺障礙 般病狀 失眠 神經質i m Μ 頭暈 : 全身倦怠 關節痛· 肌肉痛 頭痛 心悸亢進 犠行感 帐 担U Η 55 55 55 55 55 55 55 55 55 寸 寸 寸 寸 寸 寸 寸 寸 寸 寸 55 55 55 55 55 55 55 55 55 55 55 55 55 55 55 CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN O O O CN O CN —CS 一——(-Η—— ο ο mm 一— ο ο Ο 〇 87-year-old woman | Ο Ο Ο Ο 〇Ο Ο 〇 04 04 f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f ——^sD e Ο Ο Ο Ο 〇Ο Ο 〇*—1 >—1 (NO ο ο ο ο ο ο ο —— Ο (N ——fN —Ο (N ——— — ο ο Ο Ο ο ο ο ο Ο 〇ο e <Ν Ο Ο 〇〇——(S (N (S inch (S o吋一——一 5 5 Ν Ν Ν 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 ο ο ο Ο Ο 〇 (Ν (N inch - <N - ο - ο ο (Ν (Ν Η Η ◦ ο 〇 58 58 58 58 58 58 58 58 58 58 寸 寸 — — — — — — — — — — — — — ο ο ο ο ο ο —— ο ο — 一 Ο Ν (Ν S —<<Ν Ο fN ΟΟ —Ο (N Ο (N vs ooo ο ο ο 一一CM (Ν Ν Ν Ν 〇 —— ' 〇 〇 〇 〇 〇 〇 〇 〇 〇 oo oo oo Ο 〇Ο Ο ooooo Ν Ν CN ο ο —— —— ο ο ο ο Ο 〇 S S Ν 00 00 00 00 00 00 00 ( ( ( ( ( ( ( ( ( ( 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 61 Ο - oo Ο oo oo oo oo oo oo oo oo oo oo - - oo oo oo oo - - - 一 - - - - - - - - - - - - oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo Γ ΐ —— 二 —— 二 二 oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν Ν 56 Ο 〇ooo ο ο ο ο ο 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 56 oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo 〇 〇〇 oo oo oo oo Ο 〇 oo ooo "° Μ ο ο ο ο ο ο ο ο ο ο 1 1 1 1 S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S S Strong salt K 簏mu 鹬鞮s _ _ 壮 \fh K 骝峨娣en±^ rn m3 chain S 坩 § 5 堡 肚 肚 SK » | Wei _ _ face strong wmn i® ^ W- W » Seven strong姊)Κ m recorded is _ Zhuang easy to get tired: menopause index depends on S w1» a • ie mm, coffee stupid 1 11W, : headache: menopause index heart beat menopause index ~ Μ key 拗颦 3S S step _ belly mn menopause index Total Symptoms Vascular motor neurological disorders Perceptual disorders Symptoms Insomnia Neurological depression Dizziness Systemic burnout Joint pain • Muscle pain Headache 悸亢 行 Sense -15- (12) 1309983 58-year-old female> _1 — 〇〇^ Ο Ο 〇ο ο ο —Ο (N ο ο ο ο ο ψ^, 一一ο ο Ο 〇Ο 〇00 wm Ψ-^I psj >—1 ·—1 (Ν Ο (N ο ο ο ο ο Ψ-^ Τ-π (N CN ο ο Ο 〇Ο 〇ro 55-year-old female wheat - Ο 〇 〇 Ο Ο Ν Ν -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 68 Ο Ο Ο 〇 〇 Ο Ο Ν — — — — — — — — 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 68 ^t \ D —- ο — ο ο mmm —— Ο 〇 — Os S — 〇m — ^ CM Ο — (Ν一(N inch ο ο ο —— (Ν tN mm — '― —一Ο 〇«Ν m 64 Year-old female strolling fN (N - m 2 - (Ν inch * - (N inch CN - CNJ ο ο 一" fN| CN ο ο CN (Ν Ο 〇 ON <N em (N — m fN ^ — — (N tJ- m (Ν ο ο ο N N N 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 57 CM (N CM OJ ο ο Ο 〇Ο 〇o a ooo inch ο ο ο ο ο ο o oo oo oo N 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 52 (Ν 寸 ο ο ο CS CS CS CS CS CS CS CS CS CS CS 00 00 00 00 00 00 J J J J J J J J J J J J J J J J J J J J J J J J J J J J 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一 一〇Ο 〇Γ - 53-year-old female class ο ο ο ο ο Ο Ο Ο Ο — (Ν O — <N ο ο ο ο ο oo — ο ο Ο 〇Ο 〇«〇e · — ζ^ι —0 (Ν Ο CN廿〇—< (Nj ο —— ο ο 一一——————一— Ο 〇 53 53-year-old woman ο Ο Ο ο ο ο oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo N ο ο Ο 〇Ο 〇o 56-year-old female ο ο ο ο ο ο ο ο —— (Ν ooo ο ο ο ο ο T—— (Ν (N ο ο Ο 〇Ο 〇•/" lg ο ο ο ο ο ο ο ο ——(Ν ooo ο ο ο ο ο w — CM fN 一 〇Ο 〇 〇 menopause index total 6 Μ Μ * Distillation shovel! t S US SS « B阼豳 阼豳B馨W 葚mmm ss S UU VLU wj ΠΤ1 up 圜 s s OH S *ga> 撼sw line w | _ _ _ 峨 峨 ί ί ft 1»< face 1 hidden i® g _ 05 VII壮 娣 娣 w +] recorded i class is sw easy to get tired menopause index boat talk ε ΙΕ ^ ΠΕΕ si!f, um «si play m 13⁄4 headache 1 menopause index 1 heart beat menopause index Ή key phase S record | 35 mu syndrome Vascular motor disorder, sensory disorder, pathological insomnia, neurotic im Μ dizziness: generalized burnout, joint pain, muscle pain, headache, heart palpitations, sensation
N m. 展 藻 艇N m. Algae
Ws 鹬 16 (13)1309983 Μ 担 life 蘅 ΜWs 鹬 16 (13)1309983 Μ life life 蘅 Μ
S 蘧S 蘧
S 壯 合計 〇s 〇 〇〇 CC 00 卜 寸 (N 卜 〇\ ΓΜ <N 'sO m \〇 r*-i «Ti ΓΟ 卜 (N On 卜 一 〇〇 rs 〇\ m »/Ί Γ〇 <N oc σν 00 二 — yn •n (N •/Ί (N oc 00 〇 〇 00 〇〇 — — cn 56歲女性 鹚 〇 〇 〇 ” 对 —Ο (N Ο Ο 〇 o o o (了) ο ο —— — o o ο ο Ο 〇 σν S ο ο (N rn ^ —CN节 Ο — (N —r-j m ο ο 04 CN —— o o — Ο 〇 m 60歲女性 班 Ο Ο Ο Ο 〇 Ο — (N Ο Ο 〇 o o o ο ο ο ο ο o o <N (N o o ο ο Ο 〇 rj- U Ο Ο Ο Ο 〇 O CN对 Ο Ο 〇 o o o ο ο ο ο ο o o ro m o o ο ο Ο 〇 卜 55歲女性 班 —Ο Ο 〇 对 Ο Ο 〇 ——(Ν o o o ο-- ο ο o o —— o o ο ο Ο 〇 00 fc fS (Ν Ο Ο 00 Ο Ο 〇 <Ν ίΝ 对 o o o ο-- ο ο —一 CN ΟΊ 一— ο ο Ο 〇 卜 60歲女性 鹚 —<Ν Ο Ο 00 Ο Ο 〇 —ίΝ Tf· 〇 eN廿 ο ο ο ο ο o o CN <N —— ο ο Ο 〇 fc • ΓΝ Ο Ο 00 Ο Ο 〇 (N (N (N O fN (N ο ο ο ο ο o o (N ΓΜ — ο ο Ο 〇 σ\ 54歲女性 班 —(Ν Ο <Ν 00 Ο Ο 〇 O — CM O — iN ο ο ο ο ο 一— —— —— ο ο Ο 〇 •ο S —(Ν Ο (Ν 00 Ο Ο 〇 ——fN O — <N ο ο ο ο ο (N CM m r^i o o ο ο Ο 〇 卜 54歲女性 逛 Ο Ο — Ο 对 Ο Ο 〇 O 一 CN o o 〇 ο ο ο ο ο (N (N m m o o ο ο Ο 〇 二 fc 一 〇 — 〇 Tj* —Ο (N O — (N —Ο <N ——— —一 <N fN fN (N o o ο ο Ο 〇 Ό 54歲女性 班 Ο Ο Ο Ο Ο Ο Ο 〇 o o o o o o ο ο ο ο ο o o ΓΜ CM o o ο ο Ο 〇 (Ν Ο Ο Ο Ο Ο Ο Ο 〇 o o o o o o ο ο ο ◦ ο ◦ o m m o o ο ο Ο 〇 更年期指數合計 3 種類 * 您 S fc g 嫉 2S ft 3 Hf- S 餾_锊}^肚 磐娣g韹w is mmm 鎞蹈踩 S _进 Hr Hf> )&( 长 a n® 娣 e OH盛 ί^ττ1 il>7 链黑録 銮jg壯 擦E W 容易興奮 神經質 更年期指數 輩 S 鹧®™ 條_ s 脈拗蚁 +ia 1n? s m[ im/ 容易疲倦 更年期指數 s eS m m 鹽s «ss 幽肚 is κ 頭痛 更年期指數 心臟動悸 更年期指數 -Η 樓 坩 It 聲S 邂® SS nm 症候群 血管運動 神經障礙 知覺障礙 般病狀 失眠 神經質 憂鬱 頭暈 全身倦怠 關節痛· 肌肉痛 頭痛 心悸亢進 蟻行感 -17- (14) 1309983 (4 )檢討本發明之更年期障礙抑制劑之評估結果 由表4之更年期指數之合計欄之數値,計算對應全體 女丨生2 5人之停經指數。結果係如下所示。 停經指數:23 7/3 6 1与0 · 6 6 (有效) 亦即,因爲停經指數爲0 · 6 6,係於0.3至0.7之範圍內 ’所以判定由本發明之更年期障礙抑制劑係有效地治療更 年期障礙。S 壮 〇 〇 〇〇〇 CC 00 卜 inch (N 〇 〇 \ ΓΜ <N 'sO m \〇r*-i «Ti ΓΟ 卜 (N On 卜一〇〇rs 〇\ m »/Ί Γ〇 <N oc σν 00 II - yn •n (N •/Ί (N oc 00 〇〇00 〇〇 – cn 56-year-old female 鹚〇〇〇) Ο Ο (N Ο Ο 〇ooo ( ) ο ο —— oo ο ο Ο 〇σν S ο ο (N rn ^ —CN 节Ο — (N —rj m ο ο 04 CN —— oo — Ο 〇m 60-year-old female class Ο Ο Ο 〇Ο — (N Ο Ο ooooo ο ο ο ο ο oo oo j CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN CN oo oo oo CN CN CN 55 oo 55 55 55 55 55 55 55 55 55 55 55班 班 〇 〇 〇 〇 〇 〇 Ν Ν Ν Ν 〇 Ν Ν f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f f 00 o f f f f f o o o f f f f o o o f f f f o o o —一CN ΟΊ一— ο ο Ο 〇 60 60 year old female 鹚—& Ν Ν Ο 00 00 Ο Ο 〇 — Ν Ν Tf· 〇eN廿ο ο ο ο ο oo oo CN <N —— ο ο Ο 〇fc • ΓΝ Ο 00 00 Ο Ο 〇 (N (N (N (NO fN (N ο ο ο ο ο oo (N ΓΜ — ο ο Ο 〇σ\ 54-year-old female class - (Ν Ο <Ν 00 Ο Ο 〇O — CM O — iN ο ο ο ο ο —— —— — ο ο 〇 ο•ο S —(Ν Ο (Ν 00 Ο Ο 〇 - fN O — <N ο ο ο ο ο (N CM mr^ioo ο ο Ο 〇 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 54 Ο Ο 〇O a CN oo 〇ο ο ο ο ο (N (N mmoo ο ο Ο f f f f 〇 〇 j j j j j NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO NO f oo 〇Ό 〇Ό 〇Ό oo 〇Ό 〇Ό 〇Ό 〇Ό 〇Ό 〇Ό 〇Ό 〇Ό 〇Ό 〇Ό oo 〇Ό 〇Ό 〇Ό 〇Ό 〇Ό oo CM CM CM CM CM oo CM CM CM CM CM CM CM CM CM CM oo CM oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo oo ο ◦ ο ◦ ommoo ο ο Ο 〇 Menopause Index Total 3 Categories* You S fc g 嫉2S ft 3 Hf- S Distillation _锊}^ Intestines g韹w is mmm Stepping on S _ into Hr Hf>)&; (长an® 娣e OH Shengί^ττ1 il>7 chain black record 銮jg strong rub EW easy to excite neurotic menopause index generation S 鹧®TM strip _ s pulse ant +ia 1n? sm[ im/ easy to fatigue menopause Index s eS mm s «ss 肚 is is κ headache menopausal index heart dysfunction menopausal index - 坩 坩 It sound S 邂 ® SS nm syndrome vasomotor neurological disorder sensory disorder insomnia neurotic depression dizziness body burnout joint pain · muscle pain headache heart sputum ants Sense -17- (14) 1309983 (4) Review of the evaluation results of the menopausal inhibitors of the present invention From the total number of the menopausal indices in Table 4, calculate the menstruation index corresponding to 25 female students. The results are as follows. Menopause index: 23 7/3 6 1 and 0 · 6 6 (effective), that is, because the menstrual index is 0 · 6 6 within the range of 0.3 to 0.7, so it is determined that the menopausal inhibitor of the present invention is effective Treat menopausal disorders.
另外,關於症候群所屬之各症候,由上述式(Π )所 計算之指數係如下所示。此等指數係成爲對各種症候之治 療效果之判斷基準。In addition, regarding each symptom to which the syndrome belongs, the index calculated by the above formula (Π) is as follows. These indices are the basis for judging the effects of various symptoms.
血管運動神經障礙:86/128与0.67 知覺障礙般症狀:18/36 = 0.50 失眠:3 0/48 与 0.63 神經質:3 0 / 3 8与0.7 9 憂鬱:9/15 = 0.6 頭暈:2/6与0.33 全身倦怠:16/25与0.64 關節痛、肌肉痛:3 6/4 8 = 0.75 頭痛:5”0=〇.50 心悸亢進:3/84 0.38 蟻行感(formication) : 1/3与 〇·33 對於各種症候之治療效果雖不均勻’但本發明之更年 期障礙抑制劑係有效地抑制大範圍的症候。 -18-Angiopathy: 86/128 vs. 0.67 Perceptual symptoms: 18/36 = 0.50 Insomnia: 3 0/48 and 0.63 Neuroticism: 3 0 / 3 8 and 0.7 9 Melancholy: 9/15 = 0.6 Dizziness: 2/6 With 0.33 systemic burnout: 16/25 and 0.64 joint pain, muscle pain: 3 6/4 8 = 0.75 headache: 5"0 = 〇.50 palpitations: 3/84 0.38 ant sense (formation): 1/3 with 〇·33 Although the therapeutic effects on various symptoms are not uniform, the cerebral dysfunction inhibitor of the present invention effectively suppresses a wide range of symptoms.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW93134486A TWI309983B (en) | 2004-11-11 | 2004-11-11 | Medicine for inhibiting climacteric symptom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW93134486A TWI309983B (en) | 2004-11-11 | 2004-11-11 | Medicine for inhibiting climacteric symptom |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200614998A TW200614998A (en) | 2006-05-16 |
| TWI309983B true TWI309983B (en) | 2009-05-21 |
Family
ID=45072149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW93134486A TWI309983B (en) | 2004-11-11 | 2004-11-11 | Medicine for inhibiting climacteric symptom |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI309983B (en) |
-
2004
- 2004-11-11 TW TW93134486A patent/TWI309983B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200614998A (en) | 2006-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200848064A (en) | Process for producing osteocalcin-containing extract | |
| WO2007109587A2 (en) | Compositions and methods for reducing inflammation and pain associated with acidosis | |
| JP2010509199A (en) | Reduction of overweight or obesity | |
| RU2678105C2 (en) | Application of taurine for prevention and / or treatment of diseases caused by coronaviruses viruses and / or rotaviruses | |
| TWI309983B (en) | Medicine for inhibiting climacteric symptom | |
| WO2016112553A1 (en) | Pharmaceutical composition for preventing and/or treating disease caused by coronavirus and/or rotavirus | |
| CN105832759A (en) | Pharmaceutical composition for preventing and/or treating diseases caused by coronaviruses and/or rotaviruses | |
| JP7507772B2 (en) | Combination of silicon and magnesium for the prevention and treatment of muscle spasms - Patent Application 20070233633 | |
| JP2011219449A (en) | Inflammatory bowel disease therapeutic agent | |
| CN103877140A (en) | Application of saussurea involucrate culture in preparation of product for promoting bone health | |
| CN1315411C (en) | Health-care food with functions of relaxing the bowels and beautifying, and its prepn. method | |
| JP7271016B2 (en) | Use of a composition containing CHP (cyclo-hyspro) and parathyroid hormone for the prevention, amelioration or treatment of bone loss diseases | |
| EP3727436A1 (en) | Compositions and methods of treatment of ehlers-danlos syndromes | |
| ES2733579T3 (en) | Glycine as a dietary supplement for the treatment of health problems that result from underlying metabolic disorders | |
| JP4122121B2 (en) | Fat metabolism promoter and food and drink containing the same | |
| JP3975448B2 (en) | Menopause disorder inhibitor | |
| JP2008266222A (en) | Effect of collagen peptide on digital ulcer complicated with scleroderma | |
| RU2076731C1 (en) | Agent and method of organism nonspecific resistance increase at viscera morbidity | |
| CN103550410B (en) | Drug composition for losing weight, preparation containing same and preparation method of drug composition | |
| RU2384341C1 (en) | Pharmaceutical composition for psoriasis treatment | |
| CN109481446B (en) | Composition for improving body functions of pregnant woman, lying-in woman and lactating mother and fetus and preparation process | |
| CN108420891A (en) | A kind of composition and its preparation method and application for preventing and/or treating hyperuricemia | |
| Berrut et al. | Empagliflozin in the elderly | |
| CN109223766A (en) | Improve the composition and preparation process that microcirculation in human body improves the immunity of the human body | |
| CN107982413A (en) | A kind of buccal lozenge of boat sterculia seed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |